SI-BONE (SIBN) Q4 2025 earnings review
Profitability Inflection Reached, But Top-Line Growth Decelerates
SI-BONE achieved a major financial milestone in Q4: its first quarter of positive free cash flow ($0.4M) alongside record Adjusted EBITDA of $5.1M. However, this profitability inflection coincides with a visible deceleration in top-line growth and physician adoption. Worldwide revenue growth slowed to 15.0% in Q4 (down from 24.9% in Q1), and FY26 guidance implies a new, lower growth tier of 14-16%. Furthermore, management is guiding for gross margin compression in FY26 (down to ~78%) as product mix shifts and depreciation costs rise. The company has successfully proven its asset-light, high-leverage business model, but investors must now weigh improving cash generation against a cooling growth engine.
🐂 Bull Case
The company has proven its scalable hybrid commercial model, generating positive operating cash flow ($1.7M) and free cash flow ($0.4M) in Q4 while expanding Adjusted EBITDA margins.
The transition from a single-product SI joint company to a broader 'compromised bone' platform is succeeding, with new products like iFuse TORQ TNT and Bedrock Granite driving adoption in trauma and spinal pelvic fixation.
🐻 Bear Case
Revenue growth decelerated significantly in Q4 to 15.0%, and FY26 guidance of 14-16% indicates the hyper-growth phase (20%+) seen earlier in FY25 is over.
After enjoying gross margins near 79.8% in mid-2025, Q4 slipped to 79.0% and FY26 guidance projects a drop to ~78%. This is driven by non-cash depreciation from expanding surgical capacity and a mix shift toward lower-ASP trauma products.
⚖️ Verdict: ⚪
Neutral. The long-awaited transition to positive free cash flow and EBITDA is a massive de-risking event. However, the simultaneous deceleration in revenue growth, slower physician additions, and guided margin compression limit the upside potential.
Key Themes
Operating Leverage Drives Profitability Surge
Accelerating. The company is demonstrating massive operating leverage. While Q4 revenue grew 15.0%, operating expenses grew only 6.2%. This discipline caused Adjusted EBITDA to surge 176.2% YoY to $5.1 million in the quarter, completing a remarkable turnaround from a $5.1 million loss in FY24 to an $8.9 million profit in FY25.
Active Physician Growth Decelerates Sharply
Decelerating. A critical leading indicator—growth in active U.S. physicians—slowed materially in Q4. After posting 27.3%, 25.0%, and 27.0% YoY growth in Q1, Q2, and Q3 respectively, Q4 physician growth decelerated to just 18% (~1,640 total active physicians). This correlates directly with the top-line revenue slowdown.
Gross Margin Compression Trending Lower
Reversing. After quarters of steady expansion (peaking at 79.8% in Q2 and Q3), Q4 gross margin slipped to 79.0%. Management is guiding for ~78% in FY26. This multi-year stabilization at a lower tier is attributed to two factors: higher depreciation costs from new instrument sets (needed for new product launches) and a product mix shift toward trauma procedures, which typically utilize fewer implants per case (lower ASP).
Favorable Macro Reimbursement Tailwinds
SI-BONE is benefiting from a highly supportive regulatory environment. A New Technology Add-On Payment (NTAP) for iFuse TORQ TNT (up to $4,136) became effective in Q4, driving trauma adoption. Additionally, the Transitional Pass-Through (TPT) payment status for iFuse Bedrock Granite is proposed for extension into FY26, supporting the pelvic fixation segment.
New Partnerships & ASC Expansion
Management continues to expand its TAM through targeted product launches and strategic alliances. In February 2026, they launched INTRA Ti, a new fusion solution optimized for the rapidly growing Ambulatory Surgery Center (ASC) environment. They also signed a strategic distribution partnership with orthopedics giant Smith+Nephew to push iFuse TORQ into Level 1 and 2 trauma centers nationwide.
Other KPIs
Decelerating. U.S. revenue grew 13.9% YoY in Q4, a marked slowdown from the 21.2% growth seen in Q3 and the 26.6% growth in Q1. While procedure volumes remain the core engine, the slower growth rate indicates that the low-hanging fruit in physician conversion may have been captured.
Accelerating. International sales surged 38.8% YoY. Though it remains a tiny fraction of the business (~5% of total revenue), the European rollout of iFuse TORQ is finally starting to show material impact after initial regulatory delays earlier in 2025.
Stable and highly defensive. With the company now generating positive free cash flow, this cash pile completely eliminates near-term financing risks and provides ample dry powder to self-fund R&D for its upcoming 'breakthrough' spine devices.
Guidance
Decelerating. The midpoint implies 15.0% YoY growth. This represents a clear step down from the 20.2% growth achieved in FY25. The company is transitioning from a hyper-growth phase into a more mature, profitable growth phase.
Decelerating. A step down from the 79.6% achieved in FY25. This confirms earlier warnings from management regarding margin dilution from the trauma segment's lower implant-per-case ratio and elevated depreciation from aggressive instrument set buildouts.
Accelerating. OpEx grew 8.9% in FY25 but is guided to grow ~12.5% in FY26. This suggests management is ramping up investments in sales and R&D (specifically for the two new product launches planned for 2026) to defend and re-accelerate the top line.
Key Questions
Physician Growth Deceleration
Active U.S. physician additions slowed from a 27% growth rate in early 2025 to 18% in Q4. Is this a function of market saturation in the core SI joint market, or a temporary lull before new product launches re-accelerate adoption?
Operating Expense Ramp
You are guiding to ~12.5% OpEx growth in 2026, outpacing the 8.9% growth seen in 2025. Could you break down how much of this is tied to the Smith+Nephew partnership versus internal R&D for the upcoming 'breakthrough' spine device?
Smith+Nephew Partnership Economics
How does the strategic distribution partnership with Smith+Nephew for Level 1 and 2 trauma centers impact the margin profile of the iFuse TORQ line? Does this distribution model structurally lower your gross margins on those specific sales?